Rasio cepet Athira Pharma, Inc. (ATHA)

Athira Pharma, Inc. (ATHA) develops treatments for Alzheimer's disease, leveraging partnerships with medical centers and grants to study Fosgonimeton. Historical price action visualizes this trajectory, where the current figure stands at 9.40. The business operates under intense pressure from industry behemoths, yet maintains independence from market volatility by focusing on clinical trial stages and product commercialization.

This indicator determines the investment reliability of the issuer by measuring the ability to settle short-term obligations using the most liquid assets, excluding illiquid inventories. By analyzing the quick ratio, an investor assesses the financial stability of Athira Pharma, Inc. (ATHA), whose development of regenerative treatments for neurodegenerative diseases requires significant cash reserves to maintain the pace of innovation in neuroscience.